Phase II study of a modified combination of etoposide, doxorubicin, and cisplatin for patients with advanced gastric

Icli F., Karaoguz H., AKBULUT H., Dincol D., DEMİRKAZIK A., Cay F.

JOURNAL OF SURGICAL ONCOLOGY, vol.64, no.4, pp.318-323, 1997 (SCI-Expanded) identifier identifier identifier

  • Publication Type: Article / Article
  • Volume: 64 Issue: 4
  • Publication Date: 1997
  • Journal Name: JOURNAL OF SURGICAL ONCOLOGY
  • Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus
  • Page Numbers: pp.318-323
  • Keywords: etoposide, doxorubicin, cisplatin, chemotherapy, advanced gastric cancer, COOPERATIVE-ONCOLOGY-GROUP, CANCER, CHEMOTHERAPY, TRIAL, ADRIAMYCIN, EAP, ADENOCARCINOMA, CARCINOMA
  • Lokman Hekim University Affiliated: No

Abstract

Background: Based on the promising results of EAP (etoposide, doxorubicin, and cisplatin) combination, a phase II study of modified EAP combination was performed in patients with advanced gastric cancer to evaluate the response, toxicity, and survival.